Prevention of stroke for clinical purposes

被引：0

作者：

Grotemeyer, K-H. ^{[1
]}

Grotemeyer, K. C. ^{[1
]}

机构：

[1] Klinikum Saarbrucken, Neurol Klin, D-66119 Saarbrucken, Germany

来源：

NERVENHEILKUNDE | 2009年 / 28卷 / 11期

关键词：

Stroke; secondary prevention; aggregation inhibitors; anti-coagulation; costs; ACETYLSALICYLIC-ACID; SECONDARY PREVENTION; ATRIAL-FIBRILLATION; DOUBLE-BLIND; ASPIRIN; CLOPIDOGREL; TRIAL; RISK; DIPYRIDAMOLE; ATORVASTATIN;

D O I：

10.1055/s-0038-1627161

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The physician knows the guidelines from the German Neurology Society (DGN) for the prevention of a second stroke. However, for the treatment of a patient pragmatism is necessary and the costs for the system have to be regarded. Furthermore, clinical studies can leave unanswered questions. For the choice of the aggregation inhibitor the individual situation of the patient should be regarded. Blood pressure has to be observed and regulated. Lipid-lowering agents are effective for elderly patients as prevention, but not as first choice treatment. For every medical treatment, practical and clinical usefulness should be regarded.

引用

页码：789 / +

页数：6

共 50 条

[21] Secondary stroke prevention: recent developments [J].

Kranidiotis, Georgios .

SCIENTIFIC CHRONICLES, 2019, 24 (03) :266-276

[22] Antiplatelet Drugs for Ischemic Stroke Prevention [J].

Leys, Didier ;

Balucani, Clotilde ;

Cordonnier, Charlotte .

CEREBROVASCULAR DISEASES, 2009, 27 :120-125

[23] Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines [J].

Hankey, Graeme J. .

CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) :1453-1462

[24] Ischemic stroke prevention: An update on antiplatelet therapy [J].

Neill, KK ;

Luer, MS .

NEUROLOGICAL RESEARCH, 2002, 24 (04) :381-388

[25] Antiplatelet Strategies for Secondary Prevention of Stroke and TIA [J].

Ishida, Koto ;

Messe, Steven R. .

CURRENT ATHEROSCLEROSIS REPORTS, 2014, 16 (11)

[26] New Findings in Primary and Secondary Stroke Prevention [J].

Weimar, C. ;

Weber, R. ;

Hajjar, K. ;

Diener, H. C. .

AKTUELLE NEUROLOGIE, 2013, 40 (02) :70-78

[27] Validity of Composite Outcomes in Meta-Analyses of Stroke Prevention Trials: The Case of Aspirin [J].

McGrath, Emer ;

O'Conghaile, Aengus ;

Eikelboom, John W. ;

Dinneen, Sean F. ;

Oczkowski, Colin ;

O'Donnell, Martin J. .

CEREBROVASCULAR DISEASES, 2011, 32 (01) :22-27

[28] Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness [J].

Rothlisberger, Julia M. ;

Ovbiagele, Bruce .

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (04) :377-384

[29] Prevention of cardioembolic stroke [J].

Gil Nunez, Antonio .

NEUROLOGIA, 2012, 27 :15-26

[30] Naoxintong Capsule for Secondary Prevention of Ischemic Stroke: A Multicenter, Randomized, and Placebo-Controlled Trial [J].

Yu Xiao-fei ;

Zhu Xu-ying ;

Yuan Can-xing ;

Wu Dan-hong ;

Zhao Yu-wu ;

Yang Jia-jun ;

Wang Chang-de ;

Wu Wei-wen ;

Liu Xue-yuan ;

Liu Zhen-guo ;

Nie Zhi-yu ;

Deng Ben-qiang ;

Bao Huan ;

Li Long-xuan ;

Wang Chun-yan ;

Zhang Hong-zhi ;

Zhang Jing-si ;

Huang Ji-han ;

Gong Fan ;

Wang Ming-zhe ;

Guo Yong-mei ;

Sun Yan ;

Cai Ding-fang .

CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2022, 28 (12) :1063-1071

← 1 2 3 4 5 →